24 completed, 7 terminated, 6 recruiting, 6 unknown. 46 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 46 | Completed 24, Terminated 7, Recruiting 6, Unknown 6, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Unknown 2, Completed 1 |
Follow Breast Neoplasm: new trials by email Literature Review of Breast Neoplasm trials Research Report on Breast Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Tart Cherry Juice - Breast Cancer, Breast Cancer Stage I | Phase 2 | Recruiting | University of California, Davis | 86 | 2024-08-15 | 2026-03-04 |
| The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC Trilaciclib plus chemotherapy, Chemotherapy - Breast Neoplasm | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 150 | 2023-07-30 | 2023-07-24 |
| Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer Paclitaxel, Carboplatin, Trastuzumab - Breast Cancer, Breast Neoplasm | Phase 2 | Recruiting | Baylor Breast Care Center | 185 | 2023-04-18 | 2025-02-27 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 620 | 2022-12-30 | 2024-10-04 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
| TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer trifluridine/tipiracil - Breast Neoplasm, Chemotherapy Effect | Phase 2 | Completed | Borstkanker Onderzoek Groep | 52 | 2020-09-25 | 2026-05-22 |
| Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer Abemaciclib, Fulvestrant - Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Terminated | University of California, Irvine | 1 | 2020-07-23 | 2023-06-06 |
| PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer AZD6738, Olaparib, Durvalumab - Breast Neoplasm, Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 119 | 2019-10-15 | 2025-08-11 |
| Anlotinib in Metastatic HER2 Negative Breast Cancer Anlotinib Hydrochloride - Breast Neoplasm, Antineoplastic Agents | Phase 2 | Completed | Peng Yuan | 26 | 2018-07-12 | 2020-07-29 |
| Combination Study of SV-BR-1-GM With Retifanlimab SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation - Breast Cancer, Breast Neoplasm | Phase 1 / Phase 2 | Completed | BriaCell Therapeutics Corporation | 36 | 2018-03-16 | 2026-03-27 |
| A Guided Internet-delivered Individually-tailored ACT-influenced CBT Intervention to Improve Psychosocial Outcomes in Breast Cancer iACT-BC - Breast Neoplasm | Phase 2 / Phase 3 | Unknown | Linkoeping University | 128 | 2018-02-01 | 2017-09-08 |
| Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC Decitabine, Carboplatin - Breast Neoplasm | Phase 2 | Terminated | Shanghai Jiao Tong University School of Medicine | 12 | 2017-11-15 | 2022-04-06 |
| SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b - Breastcancer, Breast Neoplasm | Phase 1 / Phase 2 | Completed | BriaCell Therapeutics Corporation | 24 | 2017-05-05 | 2021-01-29 |
| A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer Megestrol Acetate 160Mg Tablet, Anastrozole 1Mg Tablet, Letrozole 2.5Mg Tablet - Breast Neoplasm | Phase 2 | Unknown | Instituto Nacional de Cancer, Brazil | 20 | 2017-03-06 | 2019-08-15 |
| Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Trilaciclib, Gemcitabine, Carboplatin - Triple-Negative Breast Neoplasms, Breast Neoplasm | Phase 2 | Terminated | G1 Therapeutics, Inc. | 102 | 2017-02-02 | 2022-03-23 |
| G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer G1T38, Fulvestrant - Carcinoma, Ductal, Breast, Breast Cancer | Phase 1 / Phase 2 | Unknown | G1 Therapeutics, Inc. | 102 | 2017-01-01 | 2023-02-15 |
| SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer SFX-01, Fulvestrant, Tamoxifen - Breast Neoplasm | Phase 2 | Completed | Evgen Pharma | 60 | 2016-10-01 | 2019-07-12 |
| Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction Ultrasound, 0.25% bupivacaine - Breast Neoplasm | Phase 2 | Unknown | Huntington Memorial Hospital | 60 | 2016-09-01 | 2016-09-23 |
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. Palonosetron, Ondansetron - Breast Neoplasm, Antineoplastic Agents | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 560 | 2015-11-05 | 2018-07-30 |
| [18F]FES PET/CT in Endocrine Refractory Breast Cancer [18F]FES - Estrogen Receptor Positive Breast Cancer, Breast Neoplasm | Phase 2 | Terminated | University of Pennsylvania | 6 | 2015-10-15 | 2026-06-11 |
Showing 20 of 46. Sign in to see all of them.
Breast Neoplasms (46) · Triple Negative Breast Neoplasms (6) · Neoplasm Metastasis (5) · Neoplasms (4) · Anxiety Disorders (1) · Brain Neoplasms (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Non-Small-Cell Lung (1) · Fatigue (1) · Ketosis (1) · Melanoma (1) · Neoplasms, Second Primary (1) · Ovarian Neoplasms (1)
Breast Diseases (46) · Neoplasms by Site (46) · Skin Diseases (46) · Skin and Connective Tissue Diseases (46) · Neoplasms (42) · Pathological Conditions, Signs and Symptoms (6) · Neoplastic Processes (5) · Pathologic Processes (5) · Neoplasms by Histologic Type (2) · Acid-Base Imbalance (1) · Acidosis (1) · Adenocarcinoma (1) · Adnexal Diseases (1) · Brain Diseases (1) · Bronchial Neoplasms (1)
Cyclophosphamide (9) · Fulvestrant (6) · Trastuzumab (5) · Carboplatin (4) · Docetaxel (4) · Doxorubicin (4) · Letrozole (4) · Paclitaxel (4) · Capecitabine (3) · Tamoxifen (3) · Anastrozole (2) · Aromatase Inhibitors (2) · Bevacizumab (2) · Epirubicin (2) · Everolimus (2)
Merck Sharp & Dohme LLC (5) · University of Washington (3) · BriaCell Therapeutics Corporation (2) · Fudan University (2) · G1 Therapeutics, Inc. (2) · National Cancer Institute (NCI) (2) · Proton Collaborative Group (2) · Tigris Pharmaceuticals (2) · AHS Cancer Control Alberta (1) · Accelerated Community Oncology Research Network (1) · Bayer (1) · Baylor Breast Care Center (1) · Borstkanker Onderzoek Groep (1) · Eisai Inc. (1) · Evgen Pharma (1)
United States (24) · United Kingdom (5) · Belgium (4) · China (4) · Spain (4) · Canada (3) · Austria (2) · Bulgaria (2) · France (2) · Germany (2) · Italy (2) · Australia (1) · Brazil (1) · Croatia (1) · Georgia (1)
George E Peoples, MD, FACS (2) · Georgiana K. Ellis, M.D. (2) · A. Elise van Leeuwen-Stok, PhD (1) · Andrew Chang, MD (1) · Andrew D Seidman, MD (1) · Andrew Tutt (1) · Antonio Llombart, MD (1) · Claudia H Arce Salinas, MD (1) · David Mankoff, MD. PhD (1) · Dr. Claudio Savulsky (1) · Emmanuel W Hudson, MD (1) · Erik Wist, MD, PhD (1) · Eugen Hug, MD (1)
PMID 11226762, PMID 12686700, PMID 12697943, PMID 1352024, PMID 15139073, PMID 15501952, PMID 16766588, PMID 17187507, PMID 17530482, PMID 18525044, PMID 19037667, PMID 19380449, PMID 19767314, PMID 19858391, PMID 20012355, PMID 20697802, PMID 20972805, PMID 21533811, PMID 22056854, PMID 22248721, PMID 22488022, PMID 22939099, PMID 23358260, PMID 24761161, PMID 25012726, PMID 25034821, PMID 25106522, PMID 25376971, PMID 25480319, PMID 25587516, PMID 25769963, PMID 26497721, PMID 26588217, PMID 27900579, PMID 30949435, PMID 3281702, PMID 3544842, PMID 38362377, PMID 40017682, PMID 6681766, PMID 9789602
2016 (2), 2018 (1)